Y-biologics Inc.

Korea Research Institute of Bioscience and Biotechnology

Samsung Electronics Co., Ltd.

Lucky Limited

Sungkyunkwan University

Industry-academic Cooperation Foundation, the Catholic University of Korea

University of Minnesota

Lg Philips Lcd Co., Inc.

Yonsei University

Hanwha Chemical Corporation

A&rt Co., Ltd.

Intocell, Inc.

Dayou Smart Aluminum Co, Ltd.

Seoul National University

Pharmabcine Inc.

Young Woo Park

Bum-chan Park

Ji Hyun Park

Jae Duk Lee

Seok Ho Yoo

Jae Eun Park

Myeoung Hee Jang

Jung Jae Yu

Ki Won Jo

Seil Jang

Chang Seok Kang

Young-Gyu Cho

Joon-Goo Jung

So-Young Choi

Jung Chae Lim

Hanmei Choi

Seung Hyun Lim

Woo Sung Lee

Joong Myung Cho

Dong Seog Eun

Jong Won Kim

Sungsub Kim

Hyun Mi Lee

Jae Won Jeon

Myung-ho Sohn

Kyu Won Cho

Jae Woo Lim

Eun-Jung Song

Si Hyung Lee

Dae Hoon Bae

Young Hwan Son

Tae Hee Lee

Jae Goo Lee

Dong Jin Kim

Mi Kyung Park

Mi La Cho

Yong Bum Lee

Ho Youn Kim

Hye Nan Kim

Hyun Ju Lee

Kyu B Han

Yeung Chul Kim

Jun Geol Ryu

Eun Sun Kim

Jong-Ho Lee

Sung Woo Kim

Eun Kyung Lee

Ho Jun Kim

Eun Young Lee

Dong Hee Lee

Yong Ho Lee

Sung-Il Chang

Soo Young Kim

Jong-Ho Park

Sung Ho Woo

Young Hee Lee

Chae Ok Yun

Hyang Sook Lee

Hee Chan Kim

Jung Dal Choi

Mi-La Cho

Hyo Jeong Hong

Sunyoung Kim

Eun Bong Lee

Jeong Ho Yoon

Jaeho Lee

Kyung Duk Moon

Semi Kim

Do Yun Kim

Taekyo Park

Jongun Cho

Doohwan Jung

Dong Heon Lee

Weon Sup Lee

Sangkwang Lee

Sanghyeon Yun

Okku Park

Beomseok Seo

Mi-ju Park

Ji Su Lee

Suho Park

Donghoon Seo

Je-Ho Lee

Jae Bong Yoon

Jong-Yeon Kim

Kook Jin Lim

Min Ji Seo

Sang Ryeol Shim

Jin San Yoo

Sena Kim

Minah Seol

Ji Yong Yoon

Kwi Hwa Kim

Byung Je Sung

Yeong Wook Song

Sang Seok Koh

Deog Young Choi

Joong Kyu Kim

Dong Eun Lee

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Antibody-drug conjugates comprising anti-B7-H3 antibodies

A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-α. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-α and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-α, it has an advantage of improving the treatment effect with lower dose.

Bispecific antibody specifically binding to IL-17A and TNF-α

A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.

Monoclonal antibody specifically binding to LAG-3 and use thereof

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.

Antibody to programmed cell death 1 (PD-1) and use thereof

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.

Cell engaging binding molecules

Systems and methods for automated voxel positioning in magnetic resonance spectroscopy ('MRS') are provided. In some aspects, a method includes receiving magnetic resonance ('MR') imaging data acquired from a subject using an MR imaging system and registering the MR imaging data to an atlas having a pre-defined volume of interest (&#x201c;VOI&#x201d;), or segmenting a region of interest (&#x201c;ROI&#x201d;) directly from the MR data. The method also includes generating registration parameters based on the registration, and computing a transformed VOI using the pre-defined VOI in the atlas and the registration parameters. Alternatively, the VOI may be obtained by directly estimating it from the ROI.

Systems and methods for automatic voxel positioning in magnetic resonance spectroscopy

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

A memory device may include a peripheral region and a cell region. The peripheral region may include a first substrate, a plurality of circuit elements disposed on the first substrate, a first insulating layer disposed on the plurality of circuit elements, and a first protective layer disposed in the first insulating layer. The cell region may include a second substrate disposed on the first insulating layer, wherein the ceil region includes a first impurity region, a channel region extending in a direction substantially perpendicular to an upper surface of the second substrate, a plurality of gate electrode layers stacked on the second substrate and adjacent to the channel region, and a first contact electrically connected to the first impurity region, wherein the first protective layer is disposed below the first impurity region, and has a shape corresponding to a shape of the first impurity region.

Vertical memory device

A memory device includes a plurality of channel regions that each extend in a direction perpendicular to an upper surface of a substrate, a plurality of gate electrode layers and a plurality of insulating layers stacked on the substrate adjacent the channel regions, each of the gate electrodes extending different lengths, and a plurality of dummy channel regions adjacent first ends of the plurality of gate electrode layers, wherein the substrate includes a substrate insulating layer formed below the plurality of dummy channel regions.

Vertical memory devices having dummy channel regions

There is provided a method of manufacturing a non-volatile memory device including: alternatively stacking a plurality of insulating layers and a plurality of conductive layers on a top surface of a substrate; forming an opening that exposes the top surface of the substrate and lateral surfaces of the insulating layers and the conductive layers; forming an anti-oxidation layer on at least the exposed lateral surfaces of the conductive layers; forming a gate dielectric layer on the anti-oxidation layer, the gate dielectric layer including a blocking layer, an electric charge storage layer, and a tunneling layer that are sequentially formed on the anti-oxidation layer; and forming a channel region on the tunneling layer.

Non-volatile memory devices and manufacturing methods thereof

Growing community of inventors

Daejeon, South Korea

Young Woo Park